Antihypertensive medications and their effects on lipid metabolism

Current Diabetes Reports

Volumn 8, Issue 3, 2008, Pages 214-220

  Deshmukh, Mrunalini ^a   Lee, Ho Won ^b   McFarlane, Samy I ^b   Whaley Connell, Adam ^b  

^a SUNY Downstate Medical Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CELIPROLOL; CHLORTALIDONE; DILEVALOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; GUANABENZ; GUANFACINE; INDAPAMIDE; LISINOPRIL; LOSARTAN; PINDOLOL; PLACEBO; TELMISARTAN; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLUCOSE METABOLISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID METABOLISM; LOW DRUG DOSE; METABOLIC DISORDER; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIHYPERTENSIVE AGENTS; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; LIPID METABOLISM; RISK FACTORS;

EID: 52649131419     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0037-7     Document Type: Review

References (35)

1. National Center for Health Statistics: Health United States, 2007 (with a chart book on the health of Americans). Available at http://CDC.gov/nchs/hus.htm. Accessed February 27,2008.
2. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
3. Vasan RS, Larson MG, Leip EP, et al.: Impact of high normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001, 345:1291-1297.
4. Perry HM Jr, Davis BR, Price TR, et al.: Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000, 284:465-471.
5. Staessen JA, Thijs L, Fagard R, et al.: Predicting cardiovascular risk using conventional vs. ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999, 282:539-546.
6. Almgren T, Persson B, Wilhelmsen L, et al.: Stroke and coronary heart disease in treated hypertension: a prospective cohort study over three decades. J Intern Med 2005, 257:496-502.
7. Andersson OK, Almgren T, Persson B, et al.: Survival in treated hypertension: follow up study after two decades. BMJ 1998, 317:167-171.
8. Laakso M, Sarlund H, Mykkanen L: Insulin resistance with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 1990, 10:223-231.
9. Lloyd-Jones DM, Evans JC, Larson MG, et al.: Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study. Arch Intern Med 1999, 159:2206-2212.
10. MacMahon SW, Macdonald GJ, Blacket RB: Plasma lipoprotein levels in treated and untreated hypertensive men and women. The National Heart Foundation of Australia Risk Factor Prevalence Study. Arteriosclerosis 1985, 5:391-396.
11. Lepira FB, M'Buyamba-Kabangu JR, Kayembe KP, Nseka MN: Correlates of serum lipids and lipoproteins in Congolese patients with arterial hypertension. Cardiovasc J S Afr 2005, 16:249-255.
12. Lind L, Berne C, Lithell H: Prevalence of insulin resistance in essential hypertension. J Hypertens 1995, 17:1457-1462.
13. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
14. McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713-718.
15. Sakurai K, Sawamura T: Stress and vascular responses: endothelial dysfunction via lectin-like oxidized low-density lipoprotein receptor-1: close relationships with oxidative stress. J Pharmacol Sci 2003, 91:182-186.
16. Sawamura T: LOX-1, a lectin-like oxidized LDL receptor identified from endothelial cells, in endothelial dysfunction. Int Congr Ser 2004, 1262:531-534.
17. Dandapat A, Hu C, Sun L, Mehta JL: Small concentrations of oxLDL induce capillary tube formation from endothetial cells via LOX-1-dependent redox-sensitive pathway. Arterioscler Thromb Vasc Biol 2007, 27:2435-2442.
18. Norata GD, Grigore L, Raselli S, et al.: Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 2007, 193:321-327.
19. Brook RD: Mechanism of different effects of antihypertensive agents on serum lipids. Curr Hypertens Rep 2000, 2:370-377.
20. Kasiske BL, Ma JZ, Kalil RS, Louis TA: Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995, 122:133-141.
21. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
22. Grimm RH, Flack JM, Grandits GA, et al.: Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA 1996, 275:1549-1556.
23. McMahan CA, Gidding SS, Fayad ZA, et al.: Risk scores predict atherosclerotic lesions in young people. Arch Intern Med 2005, 165:883-890.
24. Appel GB, Radhakrishnan J, Avram MM, et al.: Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003, 26:1402-1407.
25. Inoue T, Morooka T, Moroe K, et al.: Effect of telmisartan on cholesterol levels in patients with hypertension - Saga Telmisartan Aggressive Research (STAR). Horm Metab Res 2007, 39:372-376.
26. Taylor EN, Hu FB, Curban GC: Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006, 29:1065-1070.
27. Ward KD, Sparrow D, Vokonas PS, et al.: The relationships of abdominal obesity, hyperinsulinemia and saturated fat intake to serum lipids levels: Normal Aging Study. Int J Obes Relat Metab Disord 1994, 18:137-144.
28. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996, 334:374-381.
29. Sharma AM, Pischon T, Hardt S, et al.: Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001, 37:250-254.
30. Bélanger M, Boulay P: Effect of an aerobic exercise training program on resting metabolic rate in chronically beta-adrenergic blocked hypertensive patients. J Cardiopulm Rebabil 2005, 25:354-360.
31. Jacob S, Henriksen EJ: Metabolic properties of vasodilating beta-blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome. J Clin Hypertens (Greenwich) 2004, 6:690-696.
32. Remaley AT. Old drug, new tricks. the unexpected effect of doxazosin on high-density lipoprotein. Circ Res 2007, 101:116-118.
33. Lithell HO: Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991, 14:203-209.
34. Khan N, McAlister FA: Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006, 174:1737-1742.
35. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Am J Cardiol 1985, 55:1-15.